PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Virol Methods. Author manuscript; available in PMC 2012 January 1.
Published in final edited form as:
PMCID: PMC3018694
NIHMSID: NIHMS254683

Cross-genotypic Polyclonal Anti-HCV Antibodies from Human Ascitic Fluid

Abstract

Many anti-HCV antibodies are available, but more are needed for research and clinical applications. This study examines whether ascitic fluid from cirrhotic patients could be a source of reagent-grade antibodies. Ascitic fluid from 29 HCV patients was screened by ELISA for anti-HCV antibodies against three viral proteins: core, NS4B, and NS5A. Significant patient-to-patient variability in anti-HCV antibody titers was observed. Total ascitic fluid IgG purified by Protein-A chromatography reacted with HCV proteins in immunoblots, cell extracts, and replicon-expressing cells. Affinity-purification using synthetic peptides as bait allowed the preparation of cross-genotypic antibodies directed against pre-selected regions of HCV core, NS4B, and NS5A proteins. The performance of the polyclonal antibodies was comparable to that of monoclonal antibodies. Anti-NS4B antibody preparations reacted with genotype 1a, 1b, and 2a NS4B proteins in immunoblots and allowed NS4B to be localized in replicon-expressing cells. Summary: Ascitic fluid is an abundant source of human polyclonal cross-genotypic antibodies that can be used as an alternative to blood. This study shows the utility of selectively-purifying human polyclonal antibodies from ascitic fluid. Affinity purification allows antibodies to be selected that are comparable to monoclonal antibodies in their ability to react with targeted regions of viral proteins.

1. Introduction

Antibodies to hepatitis C virus (HCV) proteins have a number of potential uses in both research and clinical settings. Although antibodies can be made by immunizing animals, this approach has limitations. Polyclonal antibodies generated in response to viral antigen inoculation often have a low signal-to-noise ratio. Monoclonal antibodies can be difficult and costly to obtain, and often recognize a single HCV sub-genotype (Eng, et al. 2009). Additionally, many available antibodies are focused on single antigenic epitopes or regions. For example, nearly all commercially available antibodies to the core protein recognize the highly conserved region between amino acid residues 21–40(Eng, et al. 2009). As a result of these limitations, new and easy methods to obtain antibodies would be useful.

Unlike the antibodies generated in animals, the anti-HCV antibodies in patients evolve through repeated cycles of antigenic stimulation and B cell selection. For many RNA viruses, the antigenic stimulus is provided by the viral quasispecies, which expresses a vast population of closely-related isoforms of the viral proteins (Fishman and Branch. 2009). This process is expected to yield a diverse population of antibodies with superior performance characteristics.

In addition to research applications, polyclonal human antibodies have the potential to reduce transmission by neutralizing infectious HCV particles (Knodell, et al. 1976, Sanchez-Quijano, et al. 1988, Piazza, et al. 1998). Polyclonal human antibodies may also have diagnostic utility. They are used in the most sensitive Immunohistochemical (IHC) assay that has been developed for the detection of human liver cells infected with HCV (Ballardini, et al. 2002, Grassi, et al. 2006). In order to make human antibodies available for use in research and in the clinic, sources of these antibodies need to be identified. Human antibodies may be obtained by venipuncture, but the amount of blood that may be safely drawn at one time is limited to about 600 mL. Plasmapheresis allows for collection of a much larger volume of plasma, but it is an invasive procedure that requires specialized equipment.

In about 10% of patients with cirrhosis, ascitic fluid accumulates as a result of portal hypertension (Epstein. 1989, Seeff. 2002). Large volume paracentesis is used to treat diuretic refractory ascites in HCV patients with end-stage liver disease (Garcia-Tsao. 2002), potentially providing an abundant source of anti-HCV antibodies from a diverse donor population. Ascitic fluid is typically discarded as waste, but can be collected under sterile conditions. This study tests the hypotheses that reagent-grade antibodies can be prepared from ascitic fluid using affinity purification to select antibodies with desired antigenic specificities (Garcia-Tsao. 2002). It demonstrates that ascites is a source of anti-HCV antibodies that can be used to address basic questions about HCV molecular biology and pathogenesis.

2. Materials and methods

2.1. Patient selection

Forty-one adults undergoing therapeutic large volume paracentesis at Mount Sinai Medical Center in NY, NY were enrolled with IRB approval. This study was approved by the Mount Sinai Ethics Committee and subjects were included only if they were able to provide informed consent for specimen collection and medical record review. Twenty-nine subjects were infected with HCV. One patient was also co-infected with HIV-1 (IgG #29). All had a positive anti-HCV clinical antibody test; 27 of 29 had HCV RNA in serum and/or ascitic fluid. The majority of patients were genotype 1a and 1b (79%) or genotype 3a (14%); the genotype of two patients was unknown. Among 12 control subjects who lacked anti-HCV antibodies, nine had alcoholic liver disease and three had hepatitis B virus (HBV) infection. Patients with evidence of spontaneous bacterial peritonitis were excluded. Ascitic fluid was collected under sterile conditions on ice, aliquoted and stored at −70°C.

2.2. Peptides and indirect anti-HCV enzyme-linked immunosorbent assays

A collection of HCV H77 (genotype 1a) peptides and a control peptide from PDC-E2 were obtained from 21st Century Biochemicals (Marlboro, USA) or the AIDS Reagent Program (Germantown, USA). The following six peptides were used in this study: Core-2 (7–25;PQRKTKRNTNRRPQDVKFPC-amide); Core-3 (28–41;Ac-CGQIVGGVYLLPRRG-amide); Core-5 (29–46;GQIVGGVYLLPRRGPRLGV-amide; NS4B (1901–1922;Ac-ILRRHVGPGEGAVQWMNRLIAF-C-OH); NS5A (2297–2314;VETWKKPDYEPPVVHGC-OH). A peptide corresponding to an immunodominant epitope from the pyruvate dehydrogenase complex E2 subunit or PDC-E2 (Ac-CGDLLAEIETDKATI-amide) was used as a negative control. Ascitic fluid specimens were tested for activity against peptides using indirect ELISAs performed in Pierce 96-well maleimide (Rockford, USA) or NUNC IMMOBILIZER-AMINO plates (Kamstrupvej, Denmark). After peptide attachment and blocking, specimens were added and subsequently reacted with Jackson ImmunoResearch HRP-conjugated goat-anti human IgG (West Grove, USA). The HCV peptide or a control peptide (PDC-E2) were covalently attached to wells of microtiter plates and reacted in duplicate with each ascitic fluid specimen. The O.D. value of the PDC-E2 reaction was subtracted from the O.D. of the HCV reaction. Values of HCV specimens were normalized by dividing them by the cutoff value which was the mean of the control specimens plus three standard deviations. Optical Density (O.D.) was read at 450 nm, with a 650 nm reference subtraction. Normalized values greater than 1.0 were considered positive. All specimens were tested in duplicate on at least two occasions.

2.3. Preparation of crude IgG from ascitic fluid

To obtain IgG, ascitic fluid was microfiltered (0.45μ) using a GE Healthcare Quixstand (Uppsala, Sweden) hollow fiber system (CFP-4-E-4X2MA column) followed by diafiltration with PBS (pH 7.4). The fluid was concentrated 10-fold using GE Healthcare Quixstand hollow fiber system (UFP-30-C-4X2MA column) followed by diafiltration with PBS. The fluid was then run over a MabSelect Protein-A from GE Healthcare column. The column was washed with PBS until baseline absorbance was obtained. Antibody was eluted at low pH. The antibody peak was collected in the presence of 10X quench buffer (50mM NaH2PO4, pH 8.6) and extensively dialyzed against PBS. Antibody concentration was determined by O.D. at 260nm and 280nm, and purity was determined using non-denaturing SDSPAGE.

2.4. Affinity purification of core, NS4B, and NS5A antibodies

Affinity purification of anti-core, anti-NS4B, and anti-NS5A antibodies was performed by binding peptides (Core-2, NS4B, or NS5A) to Pierce SulfoLink Coupling Gels (Rockford, USA) and then exposing ascites-derived IgG to the matrix-bound peptide according to the manufacture’s protocol. Antibodies were eluted in 1ml fractions and the protein content was determined by O.D. at 260nm and 280nm.

2.5. Replicons: cell culture, immunoblotting and immunofluorescence (IF)

Huh-7.5 cells and Huh-7.5 cells with full-length (FL) and subgenomic (SG) bicistronic neomycin-expressing HCV replicons were cultured as described before (Blight, et al. 2002, Tscherne, et al. 2007). The replicons express HCV proteins of H77 (genotype 1a), Con1 (genotype 1b), J6/JFH and JFH (genotype 2a) under the control of the EMCV IRES and they express a p28 core-neomycin fusion protein under the control of the HCV IRES.

Immunoblots were performed as previously described (Walewski, et al. 2001). Briefly, proteins were fractionated in 12%Bis-Tris SDS-polyacrylamide gels and transferred to Invitrogen nitrocellulose membranes (Carlsbad, USA). Ascitic fluid, crude IgG, affinity-purified polyclonal antibodies, and mouse monoclonal antibodies were generally used at a 1:1000 dilution. The primary antibodies were detected using BioRad (Hercules, USA) goat anti-human or anti-mouse IgG (catalog #170–6521/170–6520, respectively). Monoclonal antibodies included anti-core 2M (epitope, amino acids 7–50, Alexis), anti-E2 monoclonal 3/11 (Flint, et al. 1999) and anti-NS5A monoclonal 9E10 (Lindenbach, et al. 2005).

Direct and indirect IF microscopy was performed on cells grown on glass chamber slides. Cells were washed in PBS, fixed with 4% paraformaldehyde, permeabilized with 0.2%Triton X-100, blocked with 5% goat serum, incubated with primary antibody, and then with secondary antibody. A 1:1000 dilution of ascitic fluid IgG and 1:100 dilutions of affinity-purified antibodies were used in most experiments. Coverslips were mounted with mounting media containing DAPI. Confocal microscopy was performed with a Leica (Bannockburn, USA) TCS-SP confocal laser scanning microscope with Ar-UV (350nm), Argon (488nm), and Diode (561nm) lasers. Epifluorescence microscopy was performed with a Nikon Eclipse E600 (Melville, USA). To demonstrate specificity, affinity-purified antibodies were incubated with either the HCV peptide used for purification or the PDC-E2 peptide.

2.6. Data analysis and statistical methods

Analyses were performed using the Mann-Whitney U test or the log-rank test, as appropriate, for continuous data; and using chi-square or Fisher’s exact tests for binary and ordinal data. A p value of less than 0.05 was considered significant. Data analyses were performed using Excel and JMP software (Nutley, USA).

3. Results

3.1. Baseline patient data, immunoglobulin levels and anti-HCV ELISAs

Patients with HCV had a median age of 55.5 years. HCV patients and controls were well-matched with respect to stage of liver disease (Table 1). The ascitic fluid/serum IgG ratio was about 1:5. Patients with HCV had significantly higher levels of IgG in both serum and ascitic fluid than controls (p<0.05). The median concentration of IgG in ascitic fluid from HCV patients was 549 mg/dL. Thus, a typical 6-liter large volume paracentesis provided approximately 33 g of IgG.

Table 1
Patient Characteristics

Based on published data about anti-HCV antibodies in serum (Desombere, et al. 2007, Takao, et al. 2007, Gabrielli, et al. 1996, Zhang, et al. 1995), we reasoned that the titer and profile of anti-HCV antibodies in ascitic fluid were likely to vary from patient-to-patient. Indirect ELISAs were used to identify ascitic fluid samples with high titers of antibodies against three HCV peptides: Core-2, NS4B, and NS5A. Among HCV mono-infected patients, 86% had anti-Core-2, 14% had anti-NS4B, and 24% had anti-NS5A antibodies (Fig. 1). Among HCV patients, reactivity to the Core 2 peptide was generally higher than to the other two peptides; however, the antibody profiles varied considerably. Subject 2, for example, had no detectable anti-Core 2 antibodies, but had the second highest titer of anti-NS4B antibodies. None of the 12 control subjects had anti-HCV antibodies. IgG from the ascites of patients 2, 7, 8, and 29 was purified by Protein-A chromatography. This process yielded 3.08 g (IQR = 2.41, 3.75) of IgG/liter of ascitic fluid, a recovery of approximately 60%.

Figure 1
Anti-HCV antibodies in ascitic fluid react with HCV peptides in ELISAs

3.2. Crude IgG from ascites fluid contains highly specific anti-HCV antibodies

Immunoblots and Immunofluorescence (IF) were used to test the performance of the IgG preparations. The IgG preparations differed from each other in their reactivity to HCV proteins in extracts of Huh-7.5 cells with sub-genomic (Fig. 2A–C, lanes b) and full-length (lanes c) replicons. As expected based on the variation seen in the antibody survey presented in Fig. 1, each ascites fluid IgG preparation reacted with a characteristic set of HCV protein bands. IgG #7 reacted with core (arrowhead), the core-neomycin (neo) fusion protein (arrow), and the E2 envelope protein (asterisk). The core-neo fusion protein contains the N-terminal 12 amino acids of the HCV core protein. In contrast to its high reactivity with HCV proteins IgG #7 reacted with almost no cellular proteins (Fig. 2A, lane a). IgG #8 reacted with core, the core-neomycin fusion, and NS5A (Fig. 2B, dot). IgG #2 reacted with NS5A and other non-structural proteins, but showed little reactivity to core (Fig. 2C). The positions of core, E2 and NS5A were determined using mouse or rat monoclonal antibodies (Fig. 2D, E).

Figure 2
IgG fractions from ascitic fluid produce strong and specific signals from viral proteins in immunoblots and immunofluorescence assays of Huh-7.5 cells harboring HCV replicons

The IgGs of all three subjects produced intense IF signals when reacted with replicon-containing Huh-7.5 cells (Fig. 2F–H) and produced extremely low background signals when reacted with Huh-7.5 control cells (Fig. 2I–K). The immunoblots and IF analyses indicated that the ascites fluid-derived IgG preparations contained high titers of anti-HCV antibodies and showed that ELISAs and Western blots can be used to identify preparations with antibodies directed against specific HCV proteins.

3.3. Affinity-purification of polyclonal human anti-core antibodies

Polyclonal antibodies directed against specific regions of HCV proteins were selected from the IgG preparations by using affinity purification methods. Anti-Core-2 antibodies were separately purified from IgG #7, IgG #8 and IgG #29. The average peak fraction obtained from 50 mL of crude IgG contained 0.85 mg of affinity-purified antibody. ELISAs were used to determine the increase in specificity achieved by affinity purification. Titers of anti-Core-2 and anti-Core-5 antibodies were measured before and after affinity purification of ascitic fluid IgG #8. The titer of anti-Core-2 antibodies was 1.9-fold higher than the titer of anti-Core-5 antibodies in the starting material. After affinity purification with the Core-2 peptide, the titer of anti-Core-2 antibodies was 1035-fold higher than the titer of anti-Core-5 antibodies, a 534-fold enrichment. Conversely, the titer of anti-Core-2 antibodies in the flow-through fraction was lower than the titer of anti-Core-5 antibodies, demonstrating the efficiency of the purification process (Fig 3A–C).

Figure 3
Enrichment of anti-Core-2 antibody

The experiments in Figure 4 confirm the ability of affinity-purification to generate anti-HCV antibodies with the desired specificities. IgG #29 was the starting material in panels A–C. This sample came from a patient with HIV/HCV, and demonstrates that patients with co-infection also provide adequate starting material for HCV antibody purification. This preparation contains antibodies to both the core-neo fusion protein (arrow) and the core protein (arrowhead) (Fig. 4A). Antibodies purified using the Core-2 peptide reacted with both core and core-neo proteins (Fig. 4B); whereas antibodies purified using Core-3 (amino acids 28–41) reacted with core, but not with the core-neo protein (Fig. 4C). This demonstrates that it is possible to remove unwanted antibodies from crude IgG preparations, while retaining antibodies with desired narrow specificities. Detection of the core-neo protein shows that the affinity purified polyclonal human antibodies are able to react with epitopes in the extreme N-terminal portion of the core protein.

Figure 4
Affinity-purified anti-Core, anti-NS4B, and anti-NS5A antibodies from ascitic fluid produce clear immunoblot and immunofluorescent signals

3.4. Affinity-purification and characterization of antibodies against non-structural proteins

A wide variety of biological effects have been attributed to HCV non-structural (NS) proteins (Egger, et al. 2002, Konan, et al. 2003, Tasaka, et al. 2007, Einav, et al. 2008, Brillet, et al. 2007, Randall, et al. 2007). Additional reagents are needed to characterize these proteins. An NS4B peptide from the C-terminal cytoplasmic tail (Lundin, et al. 2003) and an NS5A peptide from Domain II (Tellinghuisen, et al. 2004) were used to select antibodies directed against these non-structural proteins. IgG #2 was used as the starting material.

Affinity-purified, anti-NS5A polyclonal antibodies reacted specifically with their target, as indicated by immunoblot analysis of Huh-7.5 cells with (Fig. 4D, lanes a and b) and without replicons (Fig. 4D, lane c). Performance of the human polyclonal anti-NS5A antibodies was comparable to that of the NS5A mouse monoclonal antibody, 9E10 (Fig. 4E).

Immunoblots (Fig. 5A) and immunofluorescence (Fig. 5B–E) demonstrated the specificity of the affinity-purified polyclonal human anti-NS4B antibodies. These antibodies were highly specific for the p27 NS4B protein (Yu, et al. 2006). They reacted with both genotype 1a (H77), 1b (Con1) and genotype 2a (JFH-1) NS4B (lanes a, b, and c, respectively), but did not react with NS5A, although anti-NS5A antibodies were present in the starting material, as demonstrated by the blots shown in Figures 2C and and4D.4D. The anti-NS4B antibodies allowed a slight mobility difference between the H77 protein and the Con1 and JFH proteins to be detected in Western blots (Fig. 5A). These antibodies also produced a strong signal in cells expressing HCV replicons (Fig. 5B). Specificity of this signal was demonstrated in three ways: The IF signal was inhibited by pre-incubation with the NS4B peptide (Fig. 5C); the signal was absent from control cells lacking replicons (Fig. 5D); and it was not inhibited by pre-incubation with an irrelevant peptide (Fig. 5E).

Figure 5
Detection of NS4B protein using affinity purified anti-NS4B polyclonal antibodies

4. Discussion

Waste ascitic fluid is an abundant source of antibodies. This study demonstrates that it contains high-affinity, cross-reactive, human polyclonal anti-HCV antibodies and thus is a new source of anti-HCV antibodies. Ascitic fluid is easily obtainable. An average large volume paracentesis generates more than 30 g of IgG. Monoclonal antibodies, in contrast, often have narrow specificities and frequently recognize proteins produced by a single sub-genotype. The methods used can be applied directly to the preparation of antibodies against other viruses that cause chronic infections, provided that blood or a fluid analogous to ascitic fluid is available.

ELISAs were used to characterize the antibody profiles of ascitic fluid specimens. These profiles illustrated how greatly the anti-HCV antibody population varies from patient-to-patient. Because of this natural variability, by screening a large collection of ascitic fluid preparations it may be possible to identify antibodies capable of recognizing HCV protein domains that do not readily stimulate antibody responses in animals.

Synthetic peptides were used to affinity-purify antibodies against core, NS4B, and NS5A as a proof-of-principle. Over a milligram of anti-Core-2 antibodies was generated on average from 50 mL of ascitic fluid IgG. If the desired specificity is available, equivalent commercial antibodies cost about $3,000/mg, and monoclonal antibodies can be far more expensive if they need to be generated de novo. The anti-Core-2 affinity columns cost about $300 in consumable supplies and could be re-used several times. Affinity-purified antibodies recognized their target viral proteins in both immunoblots and in cells harboring HCV replicons. Significantly, antibodies purified with the Core-3 peptide did not react with the core-neo protein (Fig. 3D), although antibodies against the core-neo protein were present in the starting material. Similarly, antibodies purified with the NS4B peptide did not react with the NS5A protein (Fig. 5A,) although antibodies against the NS5A protein were present in the starting material (Fig. 2C). These result show that affinity-purification can be used to generate preparations of polyclonal antibodies that recognize pre-selected portions of HCV proteins. This degree of specificity is required for the use of the affinity-purified antibodies in studies of viral protein topology and intracellular localization.

The anti-NS4B antibodies allowed investigation of the electrophoretic mobility and intracellular location of the NS4B protein, an important viral constituent that is reported to interact with both viral and cellular proteins (Yu, et al. 2006). A review of the literature suggests that these affinity-purified anti-NS4B antibodies are the first antibody reagents that react with NS4B from genotype 1a, 1b, and 2a. When used in immunoblots, they revealed that there is a mobility difference between the H77 protein and the Con1 and JFH-1 proteins produced by replicons. The molecular basis of this difference is unknown, but interestingly, the high mobility (H77) form of NS4B correlates with inefficient replication in subgenomic replicons (Blight, et al. 2002). Affinity-purified anti-NS4B antibodies will facilitate the further characterization of NS4B proteins.

Human polyclonal anti-HCV antibodies may also find use in clinical settings. Published data show that human antibodies are the most effective reagents for detecting cells infected with HCV in clinical specimens by immunohistochemistry (Fenwick, et al. 2006, Grassi, et al. 2006); although, current methods lack the sensitivity needed for use in a standard assay to detect cells infected with HCV in clinical specimens. A second potential clinical application of polyclonal human anti-HCV antibodies is in the prevention of HCV transmission (Knodell, et al. 1976, Sanchez-Quijano, et al. 1988, Piazza, et al. 1998, Vanwolleghem, et al. 2008) and in the reduction of graft infection following liver transplantation (Feray, et al. 1998). The ready availability of ascites fluid makes it a potential source of antibodies for optimization of immunohistochemical assays and for therapeutic purposes, as large quantities of ascites fluid can be obtained from patients undergoing large volume paracentesis on a routine basis.

5. Conclusion

Ascitic fluid from HCV patients contains high-affinity anti-HCV antibodies that can be used to identify HCV proteins immunoblots and in cell culture models of HCV infection. In addition, these antibodies have potential utility in clinical immunohistochemistry and in the prevention of HCV transmission.

Acknowledgments

Permission to use Con1 and JFH-1 sequences was kindly provided by Drs. Bartenschlager and Wakita. Special thanks to the AIDS Research and Reference Reagent Program of the NIH for synthetic peptides. The studies were supported, in part, by NIH grants DA016156 and DK066939 (ADB); GM064118 (AK); NIAID F31 (AK); T32 DK007202 (JAG); 5T32AI007623-08 (JG); CA57973 and AI40034 (CMR); and grants from the MSSM DOM Innovation Award (ADB and TDS); and the Greenberg Medical Research Institute and the Starr Foundation (CMR).

Abbreviations

AP
affinity-purified
FL
full-length
HCV
hepatitis C virus
HIV
human immunodeficiency virus type-1
IF
immunofluorescence
IHC
immunohistochemical
NS
non-structural
S.D
standard deviation
SG
subgenomic

Footnotes

There were no conflicts of interests from the authors of this article.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • Eng FJ, Walewski JL, Klepper AL, Fishman SL, Desai SM, McMullan LK, Evans MJ, Rice CM, Branch AD. Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J Virol. 2009;83:3104–3114. [PMC free article] [PubMed]
  • Fishman SL, Branch AD. The quasispecies nature and biological implications of the hepatitis C virus. Infect Genet Evol 2009 [PMC free article] [PubMed]
  • Knodell RG, Conrad ME, Ginsberg AL, Bell CJ. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet. 1976;1:557–561. [PubMed]
  • Sanchez-Quijano A, Pineda JA, Lissen E, Leal M, Diaz-Torres MA, Garcia De Pesquera F, Rivera F, Castro R, Munoz J. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet. 1988;1:1245–1249. [PubMed]
  • Piazza M, Sagliocca L, Tosone G, Guadagnino V, Stazi MA, Orlando R, Borgia G, Rosa D, Abrignani S, Palumbo F, Manzin A, Clementi M. Sexual transmission of hepatitis C virus and prevention with intramuscular immunoglobulin. AIDS Patient Care STDS. 1998;12:611–618. [PubMed]
  • Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, Susca M, Strazzabosco M, Bellusci R, Iemmolo RM, Grazi G, Zauli D, Cavallari A, Bianchi FB. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl. 2002;8:10–20. [PubMed]
  • Grassi A, Quarneti C, Ravaioli M, Bianchini F, Susca M, D’Errico A, Piscaglia F, Tame MR, Andreone P, Grazi G, Galli S, Zauli D, Pinna AD, Bianchi FB, Ballardini G. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transpl. 2006;12:1673–1681. [PubMed]
  • Epstein M. Treatment of refractory ascites. N Engl J Med. 1989;321:1675–1677. [PubMed]
  • Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–46. [PubMed]
  • Garcia-Tsao G. Portal hypertension. Curr Opin Gastroenterol. 2002;18:351–359. [PubMed]
  • Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76:13001–13014. [PMC free article] [PubMed]
  • Tscherne DM, Evans MJ, von Hahn T, Jones CT, Stamataki Z, McKeating JA, Lindenbach BD, Rice CM. Superinfection exclusion in cells infected with hepatitis C virus. J Virol. 2007;81:3693–3703. [PMC free article] [PubMed]
  • Walewski JL, Keller TR, Stump DD, Gutierrez JA, Branch-Elliman W, Rodriguez A, Benson G, Branch AD. A target domain in the newly-discovered HCV alternate reading frame protein identified with a novel sequence analysis package. Hepatology. 2001;34:1091.
  • Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol. 1999;73:6235–6244. [PMC free article] [PubMed]
  • Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science. 2005;309:623–626. [PubMed]
  • Desombere I, Van Vlierberghe H, Weiland O, Hultgren C, Sallberg M, Quiroga J, Carreno V, Leroux-Roels G. Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. J Med Virol. 2007;79:701–713. [PubMed]
  • Takao Y, Yamada A, Yutani S, Ono T, Nagao Y, Ando E, Ide T, Itoh K, Sata M. Serum levels of IgG to the peptide of HCV1b core at positions 35–44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at positions 2132–2140 correlated with better prognosis in HCV-infected patients. Med Microbiol Immunol. 2007;196:157–164. [PubMed]
  • Gabrielli A, Zhang ZX, Cherubini G, Candela M, Savoldi S, Manzin A, Clementi M, Amoroso A, Sallberg M. Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol. 1996;105:59–64. [PubMed]
  • Zhang ZX, Chen M, Sonnerborg A, Weiland O, Sallberg M. Distinguishing acute from symptomatic chronic hepatitis C virus (HCV) infection by site-directed serology of the HCV structural proteins. J Infect Dis. 1995;171:1356–1359. [PubMed]
  • Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol. 2002;76:5974–5984. [PMC free article] [PubMed]
  • Konan KV, Giddings TH, Jr, Ikeda M, Li K, Lemon SM, Kirkegaard K. Nonstructural protein precursor NS4A/B from hepatitis C virus alters function and ultrastructure of host secretory apparatus. J Virol. 2003;77:7843–7855. [PMC free article] [PubMed]
  • Tasaka M, Sakamoto N, Itakura Y, Nakagawa M, Itsui Y, Sekine-Osajima Y, Nishimura-Sakurai Y, Chen CH, Yoneyama M, Fujita T, Wakita T, Maekawa S, Enomoto N, Watanabe M. Hepatitis C virus non-structural proteins responsible for suppression of the RIG-I/Cardif-induced interferon response. J Gen Virol. 2007;88:3323–3333. [PubMed]
  • Einav S, Sklan EH, Moon HM, Gehrig E, Liu P, Hao Y, Lowe AW, Glenn JS. The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection. Hepatology. 2008;47:827–835. [PubMed]
  • Brillet R, Penin F, Hezode C, Chouteau P, Dhumeaux D, Pawlotsky JM. The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region. J Infect Dis. 2007;195:432–441. [PubMed]
  • Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA. 2007;104:12884–12889. [PubMed]
  • Lundin M, Monne M, Widell A, Von Heijne G, Persson MA. Topology of the membrane-associated hepatitis C virus protein NS4B. J Virol. 2003;77:5428–5438. [PMC free article] [PubMed]
  • Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem. 2004;279:48576–48587. [PubMed]
  • Yu GY, Lee KJ, Gao L, Lai MM. Palmitoylation and polymerization of hepatitis C virus NS4B protein. J Virol. 2006;80:6013–6023. [PMC free article] [PubMed]
  • Fenwick F, Bassendine MF, Agarwal K, Bevitt D, Pumeechockchai W, Burt AD, Toms GL. Immunohistochemical assessment of hepatitis C virus antigen in cholestatic hepatitis after liver transplantation. J Clin Pathol. 2006;59:174–178. [PMC free article] [PubMed]
  • Grassi A, Quarneti C, Ravaioli M, Bianchini F, Susca M, D’Errico A, Piscaglia F, Tame MR, Andreone P, Grazi G, Galli S, Zauli D, Pinna AD, Bianchi FB, Ballardini G. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transpl. 2006;12:1673–1681. [PubMed]
  • Vanwolleghem T, Bukh J, Meuleman P, Desombere I, Meunier JC, Alter H, Purcell RH, Leroux-Roels G. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology. 2008;47:1846–1855. [PubMed]
  • Feray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, Reynes M, Bismuth A, Bismuth H. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med. 1998;128:810–816. [PubMed]